Clinical trial NCT06007391: Tolerance and Efficacy Nicotinamide (vitamin B3) in Dominant Optic Atrophy OPA1
Official title: Pilot Study of Tolerance and Efficacy Nicotinamide (vitamin B3) in Dominant Optic Atrophy OPA1
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Nicotinamide Adverse Reaction
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2023-08-23
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Dominant Optic Atrophy (hereafter known as DOA) is a neurodegenerative pathology of the optic nerve inducing progressive loss of central visual field and visual acuity. There is currently no proven treatment for this disease. The metabolomics work of Pascal Reynier's team revealed a specific metabolomic signature of DOA in the plasma of patients. This metabolomic signature revealed a relative deficiency in nicotinamide compared to a control population, a vitamin compound (vitamin B3) known to be neuroprotective for the optic nerve and mitochondria. Note that the investigator have also identified this nicotinamide deficiency in primary open-angle glaucoma and Leber's hereditary optic neuropathy, the other most common cause of hereditary optic neuropathy, these three optic nerve conditions sharing a common pathophysiological mechanism of mitochondrial deficit. In addition, an American team demonstrated the high neuroprotective power on the optic nerve of nicotinamide in a mouse model of glaucoma. These arguments converge towards the potential therapeutic interest of this vitamin in degenerative pathologies of the optic nerve. This is encouraged by the fact that two randomized clinical trials have confirmed a benefit of nicotinamide in glaucoma. The objective of this pilot study is to test the tolerance and efficacy of nicotinamide in DOA and DOA+ patients.


Eligibility criteria: Inclusion Criteria:

* Adult patients
* Patients with DOA or DOA+ due to a heterozygous pathogenic variant in the OPA1 gene
* Naïve patients (\> 3 months) in terms of taking nicotinamide
* Patients able to take oral medication and comply with specific study procedures
* Patients affiliated or beneficiaries of a social security scheme
* Signature of voluntary, free and informed consent to participate in the study

Exclusion Criteria:

* Asymptomatic patients (= healthy carriers of an OPA1 mutation but not having developed optic neuropathy)
* Patients with another associated severe ophthalmological pathology (advanced glaucoma, retinal pathology, etc.)
* Patients treated with Idebenone
* Patients with a level of transaminase(s) (ASAT and/or ALAT) twice higher than the high normal value.
* Pregnant, breastfeeding or parturient women
* Patients with a contraindication to nicotinamide
* Persons deprived of liberty by administrative or judicial decision
* Patients subject to a legal protection measure
* Persons undergoing psychiatric treatment under duress
* Persons unable to express their consent

Primary outcomes:
measure: Number of patient with neurologic or ophtalmological adverse event
timeFrame: at 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: Angers University Hospital
Study officials:
References: